Literature DB >> 11855986

Synthesis and nicotinic binding studies on enantiopure diazine analogues of the novel (2-chloro-5-pyridyl)-9-azabicyclo[4.2.1]non-2-ene UB-165.

Holger Gohlke1, Daniela Gündisch, Simone Schwarz, Gunther Seitz, Maria Cristina Tilotta, Thomas Wegge.   

Abstract

As part of our program aimed at optimizing therapeutic effects over toxic effects (as observed in the naturally occurring nicotinic acetylcholine receptor modulators (-)-nicotine, (-)-epibatidine, (-)-ferruginine, and (+)-anatoxin-a), we investigated the bioisosteric potential of diazines in the field of (+)-anatoxin-a-type structures. In the series of diazine analogues of deschloro-UB-165 (DUB-165, 6), bioisosteric replacement of the 3-pyridyl pharmacophoric element by a 4-pyridazinyl, 5-pyrimidinyl, or 2-pyrazinyl moiety resulted in novel nAChR ligands 7, 8, and 9. A palladium-catalyzed Suzuki cross-coupling of the 3-diethylboranylpyridine (14) and a Stille cross-coupling of the corresponding tributylstannyl diazines 15-17 with the vinyl triflate 13 of the N-protected 9-azabicyclo[4.2.1]nonan-2-one 12 constitute the key steps in the syntheses of these enantiopure anatoxinoids 6-9. Studies of the in vitro affinity for (alpha4)(2)(beta2)(3), alpha3(beta)4, and alpha7 nAChR subtypes by radioligand binding assays demonstrated that the diazine analogues 7-9 can be considered as pharmacologically attractive bioisosteres of DUB-165 (6) but with different effects on the binding affinity with regard to the diazine moiety. The pyrimidine-containing bioisostere 8 turned out to be the most active diazine analogue, which interacts potently (K(i) = 0.14 nM) with the (alpha4)(2)(beta2)(3) subtype and differentiates significantly among the nAChR subtypes investigated. The nitrogens in this anatoxinoid 8 show by far the most negative atomic charges (calculated using the AM1 Hamiltonian). This qualitatively correlates with the highest binding affinity observed for 8 for all subtypes under consideration.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11855986     DOI: 10.1021/jm010936y

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  6 in total

1.  Inhibition of protein-protein interactions with low molecular weight compounds.

Authors:  Marilyn M Matthews; David J Weber; Paul S Shapiro; Andrew Coop; Alexander D Mackerell
Journal:  Curr Trends Med Chem       Date:  2008-01-01

Review 2.  Nicotinic agonists, antagonists, and modulators from natural sources.

Authors:  John W Daly
Journal:  Cell Mol Neurobiol       Date:  2005-06       Impact factor: 5.046

3.  Cytisine-based nicotinic partial agonists as novel antidepressant compounds.

Authors:  Yann S Mineur; Christoph Eibl; Grace Young; Christopher Kochevar; Roger L Papke; Daniela Gündisch; Marina R Picciotto
Journal:  J Pharmacol Exp Ther       Date:  2009-01-22       Impact factor: 4.030

Review 4.  An overview of the synthetic routes to the best selling drugs containing 6-membered heterocycles.

Authors:  Marcus Baumann; Ian R Baxendale
Journal:  Beilstein J Org Chem       Date:  2013-10-30       Impact factor: 2.883

5.  Delineating the activity of the potent nicotinic acetylcholine receptor agonists (+)-anatoxin-a and (-)-hosieine-A.

Authors:  Holly P Parker; Alice Dawson; Mathew J Jones; Rui Yan; Jie Ouyang; Ran Hong; William N Hunter
Journal:  Acta Crystallogr F Struct Biol Commun       Date:  2022-08-09       Impact factor: 1.072

6.  Synthesis of New Functionally Substituted 9-Azabicyclo[4.2.1]nona-2,4,7-trienes by Cobalt(I)-Catalyzed [6π + 2π]-Cycloaddition of N-Carbocholesteroxyazepine to Alkynes.

Authors:  Gulnara N Kadikova; Vladimir A D'yakonov; Usein M Dzhemilev
Journal:  Molecules       Date:  2021-05-14       Impact factor: 4.411

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.